Please assess the completion status of the following clinical trial:

Trial Title: Letrozole as a Treatment of Endometrial Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* FIGO grade 1 or 2 endometrioid adenocarcinoma of the endometrium~* Post menopausal status must be demonstrated~* Signed informed consent~Exclusion Criteria:~* FIGO grade 3 endometrioid adenocarcinoma or non-endometrioid cancers of the endometrium~* Younger than 40 or postmenopausal status not established~* Pregnant or breastfeeding

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Letrozole (Type: EXPERIMENTAL): letrozole 2.5 mg PO daily for 2-3 weeks prior to hysterectomy.
- control (Type: NO_INTERVENTION): no treatemtn prior to hysterectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).